---
category: news
title: "Perimeter Medical Imaging AI Reports 2021 Financial Results and Provides Corporate Update"
excerpt: "Perimeter officially progresses to commercial stage with its first S-Series OCT installation. Clinical development of B-Series OCT with ImgAssist AI advances into late-stage validation activities with the initiation of a multi-center, randomized ..."
publishedDateTime: 2022-05-02T21:21:00Z
originalUrl: "https://www.benzinga.com/pressreleases/22/05/b26949844/perimeter-medical-imaging-ai-reports-2021-financial-results-and-provides-corporate-update"
webUrl: "https://www.benzinga.com/pressreleases/22/05/b26949844/perimeter-medical-imaging-ai-reports-2021-financial-results-and-provides-corporate-update"
ampWebUrl: "https://www.benzinga.com/amp/content/26949844"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/26949844"
type: article
quality: 48
heat: 48
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

related:
  - title: "Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights"
    excerpt: "DALLAS, May 3, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR Â® artificial intelligence (\"A.I ... the potential of combination therapy for these two agents."
    publishedDateTime: 2022-05-03T23:30:00Z
    webUrl: "https://www.kron4.com/business/press-releases/cision/20220503DA44966/lantern-pharma-reports-first-quarter-2022-financial-results-and-operational-highlights/"
    type: article
    provider:
      name: KRON4
      domain: kron4.com
    quality: 0

secured: "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;GA+wehC0+aoAHSUrd9aMkQ=="
---

